Higher Expression of Proteins in IGF/IR Axes in Colorectal Cancer is Associated with Type 2 Diabetes Mellitus

Jing Ding, Cong Li, Jie Tang, Cheng Yi, Ji-Yan Liu, Meng Qiu, Jing Ding, Cong Li, Jie Tang, Cheng Yi, Ji-Yan Liu, Meng Qiu

Abstract

Preexisting type 2 diabetes mellitus (preDM) increases occurrence and mortality of colorectal cancer (CRC). Insulin growth factor (IGF)/insulin receptor (IR) axes play an important role in the development of both diabetes and CRC. We aimed to explore the characteristics of proteins expression in IGF/IR axes in CRC tissues with preDM. Two hundred fifty CRC patients in West China hospital were included in analysis. Among them, 125 patients had history of diabetes matched by 125 CRC without diabetes at a 1:1 ratio. Immunohistochemical staining was used to detect the expression of proteins in IGF/IR axis. More positive expression of IGF-1, IGF-1R and IR were found in CRC group with diabetes than in non-diabetes group. No difference was detected in the expression of IR substrate-1, IR substrate-2, IGF-2, IGF binding protein 3, and mammalian target of rapamycin between two groups. Multivariate analysis showed that diabetes history was associated with all of the expression of IGF-1, IGF-1R and IR, and higher T staging and lymph node metastasis were respectively independent factors of IGF-1 and IGF-1R expression in CRC patients. Besides, IGF-1 expression was positively associated with IGF-1R and IR expression in all CRC tissues, and the association of IGF-1 and IR expression seemed to be closer in diabetes group than in non-diabetes group. Higher expression of IGF-1, IGF-1R and IR proteins in CRC was associated with diabetes, suggesting IGF-1/IR signaling may play a special part in development of CRC in patients with diabetes.

Keywords: Colorectal cancer; Diabetes mellitus; Insulin receptor; Insulin-like growth factor; Insulin-like growth factor receptor.

References

    1. Trends Endocrinol Metab. 2010 Oct;21(10):610-8
    1. Oncogene. 2010 Apr 29;29(17):2517-27
    1. Cancer. 2015 Apr 1;121(7):1071-8
    1. Arch Med Res. 2014 May;45(4):318-24
    1. Oncologist. 2014 Sep;19(9):951-8
    1. Diab Vasc Dis Res. 2014 Nov;11(6):390-4
    1. Hum Pathol. 1999 Oct;30(10):1128-33
    1. Anticancer Res. 2011 Jul;31(7):2541-5
    1. PLoS One. 2014 Mar 19;9(3):e91818
    1. Int J Cancer. 2010 Apr 1;126(7):1702-15
    1. Cancer Lett. 2003 Jun 10;195(2):127-37
    1. Mol Cell Biochem. 2011 Jul;353(1-2):225-33
    1. J Biol Chem. 2002 Apr 19;277(16):13620-7
    1. World J Diabetes. 2014 Jun 15;5(3):372-80
    1. Endocr Rev. 2007 Feb;28(1):20-47
    1. Diabetes Metab. 2014 Apr;40(2):120-7
    1. Biochem J. 1998 Aug 1;333 ( Pt 3):825-31
    1. Diabetes Care. 2015 Mar;38(3):495-502
    1. Asian Pac J Cancer Prev. 2013;14(10):5675-80
    1. Endocr Relat Cancer. 2013 May 21;20(3):391-401
    1. J Cancer Res Ther. 2015 Apr-Jun;11(2):295-9
    1. Br J Cancer. 2014 Apr 2;110(7):1847-54
    1. N Engl J Med. 1987 Jul 16;317(3):137-40
    1. Endocrinology. 2006 Dec;147(12):5826-34
    1. Cancer Med. 2014 Oct;3(5):1458-66
    1. Diabetes Metab Res Rev. 2009 Jan;25(1):3-12
    1. Cancer Res. 2002 Feb 15;62(4):1030-5
    1. Dis Colon Rectum. 2013 Nov;56(11):1304-19
    1. Biomed Res Int. 2015;2015:538019

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться